company background image
ABBV

AbbVie NYSE:ABBV Stock Report

Last Price

US$148.25

Market Cap

US$263.1b

7D

-4.1%

1Y

7.2%

Updated

02 Oct, 2023

Data

Company Financials +

AbbVie Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share PriceUS$148.25
52 Week HighUS$168.11
52 Week LowUS$130.96
Beta0.55
1 Month Change0.034%
3 Month Change9.81%
1 Year Change7.18%
3 Year Change68.60%
5 Year Change56.37%
Change since IPO323.57%

Recent News & Updates

AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price

Sep 25
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price

AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths

Sep 15

Recent updates

AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price

Sep 25
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 59% Above Its Share Price

AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths

Sep 15

AbbVie (NYSE:ABBV) Seems To Use Debt Quite Sensibly

Sep 07
AbbVie (NYSE:ABBV) Seems To Use Debt Quite Sensibly

AbbVie: Balance Is Everything

Sep 04

AbbVie: Still A Buy According To Buffett's 10xEBT Rule

Aug 23

Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?

Aug 03

Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors

Jul 28

AbbVie: Loss Of Exclusivity Is A Natural End Process

Jul 21

More Challenges Await AbbVie Following A Disappointing Quarter

Jul 14

AbbVie: Use This Buying Opportunity (Rating Upgrade)

Jul 06

Is There An Opportunity With AbbVie Inc.'s (NYSE:ABBV) 44% Undervaluation?

Jun 21
Is There An Opportunity With AbbVie Inc.'s (NYSE:ABBV) 44% Undervaluation?

AbbVie: A Pharmaceutical Powerhouse Despite Humira Challenges

Jun 16

AbbVie Stock May Be Falling On Humira LOE - But Investors Shouldn't Panic

Jun 05

Is AbbVie (NYSE:ABBV) Using Too Much Debt?

May 22
Is AbbVie (NYSE:ABBV) Using Too Much Debt?

An Intrinsic Calculation For AbbVie Inc. (NYSE:ABBV) Suggests It's 43% Undervalued

Mar 17
An Intrinsic Calculation For AbbVie Inc. (NYSE:ABBV) Suggests It's 43% Undervalued

AbbVie, Capsida expand team up to develop genetic therapies for eye diseases

Feb 23

Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet?

Feb 15
Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet?

Is AbbVie Stock A Buy After Earnings? Consider Revenue Outlook And Valuations

Feb 13

AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell?

Feb 05

AbbVie: Why The Company Is Still Overvalued

Jan 29

BioMed X, AbbVie extend partnership to focus on immunology research

Jan 17

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.48

Jan 07
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.48

2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit

Jan 01

AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

Dec 21
AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

If EPS Growth Is Important To You, AbbVie (NYSE:ABBV) Presents An Opportunity

Dec 20
If EPS Growth Is Important To You, AbbVie (NYSE:ABBV) Presents An Opportunity

AbbVie: Clouds Keep Thickening Due To Lack Of Revolutionary Drugs

Dec 13

AbbVie: I Won't Sell Till P/E Reaches 14x

Dec 07

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.48

Dec 02
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.48

AbbVie to pay $54.4M to resolve lawsuit linked to Alzheimer's drug Namenda

Nov 16

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.48

Nov 16
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.48

AbbVie candidate for postoperative atrial fibrillation fails in mid-stage trial

Nov 07

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.48

Oct 31
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.48

Shareholder Returns

ABBVUS BiotechsUS Market
7D-4.1%-1.4%-1.1%
1Y7.2%6.2%14.1%

Return vs Industry: ABBV exceeded the US Biotechs industry which returned 6.2% over the past year.

Return vs Market: ABBV underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is ABBV's price volatile compared to industry and market?
ABBV volatility
ABBV Average Weekly Movement2.6%
Biotechs Industry Average Movement9.1%
Market Average Movement5.5%
10% most volatile stocks in US Market14.1%
10% least volatile stocks in US Market2.6%

Stable Share Price: ABBV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201250,000Rick Gonzalezhttps://www.abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine.

AbbVie Inc. Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
ABBV fundamental statistics
Market CapUS$263.10b
Earnings (TTM)US$8.64b
Revenue (TTM)US$56.02b

30.3x

P/E Ratio

4.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABBV income statement (TTM)
RevenueUS$56.02b
Cost of RevenueUS$16.54b
Gross ProfitUS$39.48b
Other ExpensesUS$30.85b
EarningsUS$8.64b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)4.89
Gross Margin70.47%
Net Profit Margin15.41%
Debt/Equity Ratio476.0%

How did ABBV perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

120%

Payout Ratio

Does ABBV pay a reliable dividends?

See ABBV dividend history and benchmarks
When do you need to buy ABBV by to receive an upcoming dividend?
AbbVie dividend dates
Ex Dividend DateOct 12 2023
Dividend Pay DateNov 15 2023
Days until Ex dividend9 days
Days until Dividend pay date43 days

Does ABBV pay a reliable dividends?

See ABBV dividend history and benchmarks